Drug Profile
FBTA 05
Alternative Names: Bi20; FBTA05; LymphomunLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator TRION Pharma
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia
Most Recent Events
- 30 Sep 2015 No recent reports of development identified - Phase-I/II for Chronic lymphocytic leukaemia in Germany (IV)
- 30 Sep 2015 No recent reports of development identified - Phase-I/II for B-cell lymphoma in Germany (IV)
- 13 Jun 2010 Efficacy, adverse events and pharmacokinetics data from a compassionate use trial in Non-Hodgkin's lymphoma and Chronic lymphocytic leukaemia presented at the 15th Congress of the European Hematology Association (EHA-2010)